Tubeless Insulin Pump Market Size & Growth Forecast 2027–2036, By Segments (End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Tubeless Insulin Pump Market size was around USD 2.43 Billion in 2026 and is slated to grow at 19.86% CAGR from 2027 to 2036, exceeding USD 14.87 Billion by 2036. The industry revenue for 2027 is calculated at USD 2.85 Billion.
Get more details on this report
Request Free Sample ReportTubeless Insulin Pump Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 45.79% in 2026, supported by advanced healthcare infrastructure, diabetes awareness, connected care adoption, and acceptance of wearable medical technologies.
- Asia Pacific is the fastest-growing region as rising diabetes burden, improving healthcare access, digital health adoption, and chronic disease management efforts support wider use.
Segment Momentum
- Home care leads the market because patients increasingly prefer convenient diabetes management outside clinical settings, supported by wearable devices that provide continuous insulin delivery and greater daily flexibility.
- Home care is also the fastest-growing segment as rising awareness of self-management, expanding remote patient monitoring, and the shift toward home-based healthcare continue to accelerate adoption of tubeless insulin pumps.
Market Expansion Drivers
- Rising global diabetes prevalence driving demand for advanced continuous insulin delivery systems
- CGM integration enabling automated closed-loop insulin dosing and real-time glucose control
- Expanding telehealth-enabled diabetes management platforms improving remote insulin therapy optimization
Leading Market Participants
- Top companies in the tubeless insulin pump market include Insulet Corporation (United States), EOFlow Co., Ltd. (South Korea), Roche Holding AG (Switzerland), Terumo Corporation (Japan), Debiotech S.A. (Switzerland), Medtrum Technologies Inc. (China), MicroTech Medical (Hangzhou) Co., Ltd. (China), PharmaSens AG (Switzerland), Tandem Diabetes Care, Inc. (United States), Medtronic plc (Ireland)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 2.43 Billion
- 2027 Estimated Market Size: USD 2.85 Billion
- Projected Market Size: USD 14.87 Billion by 2036
- Growth Forecast: 19.86% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Home Care (End-use)
- Emerging Opportunity Segment: Home Care (End-use)
Market Growth Drivers and Industry Trends
Rising global diabetes prevalence driving demand for advanced continuous insulin delivery systems
The increasing burden of diabetes worldwide will drive the tubeless insulin pump market growth as healthcare providers and patients seek more effective technologies for long-term glucose management. Growing numbers of individuals with insulin-dependent diabetes are creating demand for delivery systems that provide continuous insulin administration while reducing the complexity associated with multiple daily injections. Tubeless insulin pumps offer greater mobility, discreet wearability, and flexible insulin dosing, helping improve treatment adherence and lifestyle convenience. As diabetes management increasingly emphasizes personalized therapy and consistent glycemic control, advanced wearable insulin delivery devices are becoming an integral component of comprehensive disease management strategies.
CGM integration enabling automated closed-loop insulin dosing and real-time glucose control
Advances in integrated diabetes technologies are transforming insulin therapy, which will propel the tubeless insulin pump market growth through the adoption of automated insulin delivery systems. The combination of continuous glucose monitoring with tubeless insulin pumps enables real-time glucose data exchange, allowing algorithms to automatically adjust insulin administration based on changing glucose levels. This closed-loop approach reduces the need for frequent manual intervention while supporting more precise glucose management throughout daily activities and overnight periods. Improved interoperability between monitoring devices and insulin delivery platforms also enhances patient confidence by simplifying therapy management and reducing the burden of routine diabetes care.
Expanding telehealth-enabled diabetes management platforms improving remote insulin therapy optimization
The rapid adoption of digital healthcare services is strengthening remote diabetes care, and the tubeless insulin pump market is benefiting from greater integration with telehealth-enabled management platforms. Connected insulin pump systems allow healthcare professionals to access therapy data remotely, evaluate glucose trends, and make timely adjustments to treatment plans without requiring frequent in-person consultations. Cloud-based monitoring tools facilitate ongoing communication between patients and care teams while supporting personalized therapy optimization based on continuously collected clinical information. These digital care ecosystems improve care coordination by enabling proactive intervention and more efficient long-term management of insulin-dependent diabetes.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global diabetes prevalence driving demand for advanced continuous insulin delivery systems | 2% | High | North America, Europe | High | Near Term |
| CGM integration enabling automated closed-loop insulin dosing and real-time glucose control | 2% | High | North America, Europe | High | Near Term |
| Expanding telehealth-enabled diabetes management platforms improving remote insulin therapy optimization | 1.8% | High | North America, Asia Pacific | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
Holding the largest share of the tubeless insulin pump market, North America represented 45.79% in 2026, supported by high diabetes awareness, advanced healthcare infrastructure, and strong adoption of connected diabetes management technologies. Patients and healthcare providers are increasingly seeking insulin delivery solutions that offer greater flexibility, convenience, and integration with digital monitoring systems. Favorable acceptance of wearable medical devices, continued innovation in diabetes care, and growing emphasis on patient-centered disease management are reinforcing demand for tubeless insulin delivery systems across the region.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is emerging as the fastest-growing region as the diabetes burden expands alongside urbanization, changing lifestyles, and improvements in healthcare access. Greater awareness of modern insulin delivery options is encouraging patients and clinicians to consider wearable and less intrusive alternatives to conventional insulin administration. Expanding healthcare infrastructure, increasing digital health adoption, and efforts to improve chronic disease management are also creating favorable conditions for wider use of tubeless insulin pumps.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Connected Diabetes CareThe U.S. tubeless insulin pump market is driven by growing preference for wearable diabetes management solutions integrated with continuous glucose monitoring. Healthcare providers increasingly support connected platforms that simplify insulin delivery and improve patient convenience.
Germany 🇩🇪
Technology-Based Diabetes ManagementGermany encourages adoption of tubeless insulin pumps through strong interest in digital diabetes care and clinically validated medical technologies. German healthcare providers prioritize reliable devices that integrate seamlessly with broader diabetes management platforms.
Japan 🇯🇵
User-Friendly Therapy SolutionsJapan emphasizes compact, patient-friendly tubeless insulin pump technologies that support long-term diabetes management. Healthcare providers in Japan increasingly value devices offering ease of use, discreet wearability, and dependable glucose management integration.
South Korea 🇰🇷
Digital Health IntegrationSouth Korea supports the tubeless insulin pump market through expanding digital healthcare infrastructure and growing adoption of wearable medical technologies. Local healthcare providers prioritize connected insulin delivery systems that improve treatment monitoring and patient engagement.
France 🇫🇷
Personalized Diabetes TreatmentFrance advances the tubeless insulin pump market by encouraging personalized diabetes care supported by modern wearable technologies. French clinicians increasingly incorporate connected insulin delivery devices into comprehensive long-term disease management strategies.
Italy 🇮🇹
Wearable Therapy AdoptionItaly continues integrating tubeless insulin pumps into diabetes care as healthcare providers seek practical alternatives to conventional insulin delivery. Italian patients and clinicians increasingly favor wearable systems that support flexible daily disease management routines.
Segment Leadership and Growth Trends
Tubeless Insulin Pump Market Share (%), by End-use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd-use Segment Analysis: Home Care (Largest & Fastest-Growing Segment)
Holding the largest share of the tubeless insulin pump market, the home care segment emerged as the dominant segment in 2026 and continued to be the fastest-growing application area. The increasing preference for convenient diabetes management outside traditional clinical settings has accelerated the adoption of tubeless insulin pumps among patients seeking greater flexibility and independence. These devices enable continuous insulin delivery with minimal disruption to daily routines, while their compact and wearable design supports improved treatment adherence. Growing awareness of self-management solutions, rising acceptance of remote patient monitoring, and the broader shift toward home-based healthcare further reinforce the segment’s leadership and sustained expansion.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End-use | Home Care, Hospitals & Clinics, Others | Home Care | Home Care |
Competitive Landscape and Market Positioning
Key companies in the tubeless insulin pump market:
- Insulet Corporation (United States)
- EOFlow Co., Ltd. (South Korea)
- Roche Holding AG (Switzerland)
- Terumo Corporation (Japan)
- Debiotech S.A. (Switzerland)
- Medtrum Technologies, Inc. (China)
- MicroTech Medical (Hangzhou) Co., Ltd. (China)
- PharmaSens AG (Switzerland)
- Tandem Diabetes Care, Inc. (United States)
- Medtronic plc (Ireland)
Innovation in patient convenience and connected diabetes management is reshaping competition within the Tubeless Insulin Pump Market as manufacturers work to improve usability, device reliability, and integration with digital health platforms. Companies are moving beyond basic insulin delivery functions by emphasizing discreet designs, simplified operation, and data-driven management features that align with evolving patient expectations. Competitive pressure is also increasing around clinical validation, regulatory readiness, and ecosystem compatibility, as users and healthcare providers increasingly evaluate solutions based on overall treatment experience rather than device functionality alone. Firms that can combine technological refinement with strong patient engagement strategies are better positioned to influence adoption patterns.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Insulet Corporation (United States) | |||||||
| EOFlow Co. Ltd. (South Korea) | |||||||
| Roche Holding AG (Switzerland) | |||||||
| Terumo Corporation (Japan) | |||||||
| Debiotech S.A. (Switzerland) | |||||||
| Medtrum Technologies Inc. (China) | |||||||
| MicroTech Medical (Hangzhou) Co. Ltd. (China) | |||||||
| PharmaSens AG (Switzerland) | |||||||
| Tandem Diabetes Care Inc. (United States) | |||||||
| Medtronic plc (Ireland) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Medtrum Technologies | Apr-26 | Medtrum Technologies initiated commercial expansion of its TouchCare AID system across five Southeast Asian countries through a strategic distribution partnership with Zuellig Pharma. The agreement expands the platform's international footprint into Malaysia, Thailand, Vietnam, Indonesia, and the Philippines. |
| Insulet | Jan-26 | Insulet achieved full commercial availability for the Omnipod 5 G6 and G7 interoperable versions in France following reimbursement approval from Assurance Maladie. The regulatory clearance expands access to the tubeless automated insulin delivery platform for approximately 220,000 eligible patients. |
| Tandem Diabetes Care | Nov-25 | Tandem Diabetes Care prepared for the 2026 commercial rollout of its Mobi Tubeless insulin pump following regulatory FDA clearance of its Android-compatible mobile application. The launch marks a critical category expansion into the tubeless segment alongside ongoing corporate restructuring initiatives. |
| ViCentra | Sep-25 | ViCentra secured $85 million in funding to scale up its European manufacturing infrastructure and accelerate development of the Kaleido 2 insulin pump. The capital injection funds the company’s planned 2026 launch and eventual expansion into the highly competitive United States market. |
| MicroTech Medical | Sep-25 | MicroTech Medical obtained CE Mark certification under the EU Medical Device Regulation for its tubeless patch pump system. The certification clears the path for commercial entry into European markets and has prompted distribution negotiations within Germany and the Benelux region. |
| EOFlow | Jul-25 | EOFlow finalized a corporate restructuring plan and pivoted its commercial strategy toward South Korea and Southeast Asia. The reorganization includes an updated product pipeline centered on developing a next-generation EOPatch device featuring an extended 96-hour continuous wear capacity. |
| Insulet | May-25 | Insulet secured FDA clearance for an Omnipod 5 software update that expands the automated insulin delivery platform's indicated use to pediatric patients aged two to five years. The regulatory approval significantly widens the target addressable demographic within the tubeless market segment. |
| Roche Diabetes Care | Mar-25 | Roche Diabetes Care established an interoperability partnership with Dexcom to integrate the Accu-Chek Solo patch pump with the Dexcom G7 continuous glucose monitoring system. The collaboration expands closed-loop treatment choices for European patients seeking flexible, integrated diabetes management systems. |
| Insulet | Aug-24 | Insulet deployed a US$200 million investment to expand its manufacturing operations in Johor, Malaysia. The strategic facility expansion is designed to scale up production capacity and strengthen the global supply chain for the company’s Omnipod tubeless insulin pump product line. |
| F. Hoffmann-La Roche | — | F. Hoffmann-La Roche partnered with a European academic diabetes research consortium to invest in the next-generation Accu-Chek Solo platform. The development program focuses on extending pod wear time to seven days and introducing an upgraded automated insulin delivery algorithm. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Tubeless Insulin Pump Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Patient Age Group | Pediatric, Adult |
| Pump Wear Duration | Short-Wear, Extended-Wear |
| Pump Control Method | Smartphone/App-Controlled, Dedicated Controller, Automated Closed-Loop Control |
Tubeless Insulin Pump Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Patient Adoption and Switching Dynamics |
|
| Reimbursement and Payer Coverage Landscape |
|
| Provider Workflow and Care Delivery Impact |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current revenue of the tubeless insulin pump market?
What is the forecasted size of the tubeless insulin pump industry?
How is integrated diabetes technology reshaping demand for tubeless insulin pumps?
Why are connected care platforms becoming strategically important in the tubeless insulin pump market?
Why is home care the leading end-use segment in the tubeless insulin pump market?
What is fueling the rapid growth of the home care segment in the tubeless insulin pump market?
Why does North America lead the tubeless insulin pump market?
How is Asia Pacific creating growth opportunities for tubeless insulin pumps?
Which companies are driving growth in the tubeless insulin pump landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization